PlainPharmaWatch

CMS Open Payments · Program Year 2024

Impel Pharmaceuticals LLC

Impel Pharmaceuticals LLC reported $15,807.71 across General Payments, Research, and Ownership to 1,000 physicians and teaching hospitals across 1,000 transactions.

See the rankings → How this is sourced
$15.8K
All-tracks total
1,000
Transactions
1,000
Recipients
#1570
of 1,925 companies

Impel Pharmaceuticals LLC reported $15,807.71 across all CMS Open Payments tracks (General + Research + Ownership) to 1,000 physicians and teaching hospitals in Program Year 2024 - ranking #1570 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $15,807.71, averaging $15.81 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer impel-pharmaceuticals-llc Impel Pharmaceuticals LLC

$15.8K · #1570/1,925 · 0.0% industry · PY2024

  • TOT $15.8K
  • RANK #1570
  • SHARE 0.0%
  • TXN 1,000
  • RCP 1,000
  • CAT 1
  • GEN $15.8K
  • TOP1 1.2%
  • PY 2024

Volume peers

Nearest volume peer: Stereotaxis Inc ($15.7K)

Monaghan Medical Corporation$16.0KHoya Surgical Optics GmbH$15.9KImpel Pharmaceuticals LLC (t…$15.8KStereotaxis Inc$15.7KGreat Lakes Medical Services…$15.4K
All-tracks payment totals near Impel Pharmaceuticals LLC (CMS Open Payments PY2024)

Impel Pharmaceuticals LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Impel Pharmaceuticals LLC

Averaging $15.81 per transaction and $15.81 per recipient, Impel Pharmaceuticals LLC's Program Year 2024 total comes to $15,807.71 across 1,000 transactions and 1,000 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1570 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $15.8K, accounting for 100.0% of this company's General Payments and 1,000 transactions.

General Payment Breakdown by Type

Across 1 types of general payments, Impel Pharmaceuticals LLC's largest category was "Food and Beverage" at $15.8K - 100.0% of General Payments.

How Impel Pharmaceuticals LLC divides its payments

Ranked by total dollars reported per category

1. Food and Beverage$15.8K
Payment Type Amount Transactions
Food and Beverage $15.8K 1,000

Recipient Concentration in General Payments

The five largest recipient relationships account for $826.93 (5.2%) of $15,807.71 in this company's General Payments records across 521 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Impel Pharmaceuticals LLC

The five named recipients with the highest reported General Payments from this company

Roger Chapman$190.05Jessica Horwitz$171.23Nicole Rothman$165.65Eric Baron$150.96Aurora Pajeau$149.04
  1. 1

    Roger Chapman

    $190.05 across 12 reported transactions

  2. 2

    Jessica Horwitz

    $171.23 across 10 reported transactions

  3. 3

    Nicole Rothman

    $165.65 across 8 reported transactions

  4. 4

    Eric Baron

    $150.96 across 12 reported transactions

  5. 5

    Aurora Pajeau

    $149.04 across 7 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Impel Pharmaceuticals LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Impel Pharmaceuticals LLC.

Ultradent Products Inc

HHI 36

OWP Pharmaceuticals, Inc.

HHI 35

Dilon Technologies, Inc.

HHI 35

Boehringer Ingelheim Pharmaceuticals, Inc.

HHI 34

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Impel Pharmaceuticals LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Impel Pharmaceuticals LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.